(Q34030136)

30 July 2017

1 reference

title

Raloxifene: a review of its use in postmenopausal osteoporosis (English)

1 reference

postmenopausal osteoporosis

30 July 2017

0 references

1 reference

D Clemett

1

1 reference

PubMed ID

10983739

30 July 2017

C M Spencer

series ordinal

2

1 reference

30 July 2017

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

60

1 reference

30 July 2017

379-411

1 reference

30 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060020-00013

30 July 2017

0 references

cites work

Treatment of postmenopausal osteoporosis with transdermal estrogen

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200060020-00013

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200060020-00013

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200060020-00013

Decline in physical function following hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200060020-00013

Recovery of Function After Hip Fracture The Role of Social Supports

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200060020-00013

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200060020-00013

Hormone replacement therapy and risk of venous thromboembolism: population based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200060020-00013

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

21 January 2018

1 reference

12 December 2020

Attitudes of women toward hormone therapy and prevention of heart disease

1 reference

12 December 2020

Hormone therapy to prevent disease and prolong life in postmenopausal women

1 reference

12 December 2020

Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate

1 reference

12 December 2020

Basic guide to the mechanisms of antiestrogen action

1 reference

12 December 2020

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

1 reference

12 December 2020

Therapeutic potential of selective estrogen receptor modulators.

1 reference

12 December 2020

Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group

1 reference

12 December 2020

Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis

1 reference

12 December 2020

Guidelines for diagnosis and management of osteoporosis

1 reference

12 December 2020

Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model

1 reference

12 December 2020

The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial

1 reference

12 December 2020

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

1 reference

12 December 2020

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

1 reference

12 December 2020

Can estrogens prevent neurodegeneration?

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer

1 reference

12 December 2020

Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)

1 reference

12 December 2020

Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.

1 reference

12 December 2020

A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer

1 reference

12 December 2020

Treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study

1 reference

12 December 2020

Coronary heart disease mortality and adjuvant tamoxifen therapy

1 reference

12 December 2020

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

12 December 2020

Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis

1 reference

12 December 2020

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

12 December 2020

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

1 reference

12 December 2020

Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES)

1 reference

12 December 2020

1 reference

12 December 2020

Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen.

1 reference

12 December 2020

Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance

1 reference

12 December 2020

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

1 reference

12 December 2020

Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.

1 reference

12 December 2020

Risk of venous thromboembolism in users of hormone replacement therapy

1 reference

12 December 2020

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

12 December 2020

The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature

1 reference

12 December 2020

Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone.

1 reference

12 December 2020

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

A prospective study on socioeconomic aspects of fracture of the proximal femur

1 reference

12 December 2020

The effects of raloxifene on tibia histomorphometry in ovariectomized rats

1 reference

12 December 2020

Raloxifene and estrogen: comparative bone-remodeling kinetics

1 reference

12 December 2020

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

1 reference

12 December 2020

Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis

1 reference

12 December 2020

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

1 reference

12 December 2020

Coronary heart disease in women, randomized clinical trials, HERS and RUTH

1 reference

12 December 2020

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Clinical effects of raloxifene hydrochloride in women

1 reference

12 December 2020

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

12 December 2020

Raloxifene preserves bone strength and bone mass in ovariectomized rats

1 reference

12 December 2020

Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene

1 reference

12 December 2020

Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones

1 reference

12 December 2020

Estrogen therapy in postmenopausal women: effects on cognitive function and dementia

1 reference

12 December 2020

Who are candidates for prevention and treatment for osteoporosis?

1 reference

12 December 2020

Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

1 reference

12 December 2020

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

1 reference

12 December 2020

Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group

1 reference

12 December 2020

Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator

1 reference

12 December 2020

Bone response to termination of oestrogen treatment

1 reference

12 December 2020

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

1 reference

12 December 2020

Hormone replacement therapy: compliance and cost after screening for osteoporosis.

1 reference

12 December 2020

Perspective. How many women have osteoporosis?

1 reference

12 December 2020

Selective estrogen receptor modulators and postmenopausal women's health

1 reference

12 December 2020

Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits

1 reference

12 December 2020

Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells

1 reference

12 December 2020

Long-term fracture prediction by bone mineral assessed at different skeletal sites

1 reference

12 December 2020

Management of established osteoporosis

1 reference

12 December 2020

In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators

1 reference

12 December 2020

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

12 December 2020

Osteoporosis. Frequency, consequences, and risk factors

1 reference

12 December 2020

Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens

1 reference

12 December 2020

Emerging therapies for the prevention or treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium

1 reference

12 December 2020

Effects of raloxifene hydrochloride on the endometrium of postmenopausal women

1 reference

12 December 2020

A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women

1 reference

12 December 2020

Multinucleation in normally fertilized embryos is associated with an accelerated ovulation induction response and lower implantation and pregnancy rates in in vitro fertilization-embryo transfer cycles.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women

1 reference

12 December 2020

Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium

1 reference

12 December 2020

The prevention and treatment of osteoporosis

1 reference

12 December 2020

Postmenopausal hormone therapy and mortality.

1 reference

12 December 2020

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

12 December 2020

Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia

1 reference

12 December 2020

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

12 December 2020

Prospective study of exogenous hormones and risk of pulmonary embolism in women

1 reference

12 December 2020

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats

1 reference

12 December 2020

Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study

1 reference

12 December 2020

Long-term estrogen replacement therapy prevents bone loss and fractures

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.2165/00003495-200060020-00013

Identifiers

DOI

1 reference

PubMed ID

10983739

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

10983739